Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

IMV Inc. (T:IMV)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for IMV within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Apr 18, 2019 11:05 ET
IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that two of its abstracts have been accepted for presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO
Read full article
Apr 16, 2019 13:31 ET
IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today issued the following statement regarding recent market activity.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.56
--
--
Price to Sales - TTM
475.11
19.91
19.21
Price to Book - most recent quarter
47.33
3.52
3.45
Price to Cash Flow per share - TTM
--
14.25
11.72
Price to Free Cash Flow per share - TTM
--
5.76
14.63
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 31, 2019231,03529,335
Mar 15, 2019201,7002,011
Feb 28, 2019199,68919,669
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
What do insiders prefer: traditional or alternative Healthcare stocks? https://www.canadianinsider.com/featured-report/what-do-insiders-prefer-traditional-or-alternative-healthcare-stocks $HMMJ.CA $WEED.CA $BHC $CGC $ACB.CA $IMV.CA
Nov 09, 2018 10:58 am
INK Staff's picture
What do insiders prefer: traditional or alternative Healthcare stocks? https://www.canadianinsider.com/featured-report/what-do-insiders-prefer-traditional-or-alternative-healthcare-stocks $HMMJ.CA $WEED.CA $BHC $CGC $ACB.CA $IMV.CA
Nov 09, 2018 10:58 am
Ted Dixon's picture
Insiders still buying at ImmunoVaccine. Free INK Research company report for logged in users: https://www.canadianinsider.com/featured-report/insiders-still-buying-immunovaccine $IMV.CA $IBB
May 12, 2017 09:09 am
INK Staff's picture
Insiders still buying at ImmunoVaccine. Free INK Research company report for logged in users: https://www.canadianinsider.com/featured-report/insiders-still-buying-immunovaccine $IMV.CA $IBB
May 12, 2017 09:09 am

Twitter

Search (past week) for $IMV.CA

StockTwits

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
What do insiders prefer: traditional or alternative Healthcare stocks? https://www.canadianinsider.com/featured-report/what-do-insiders-prefer-traditional-or-alternative-healthcare-stocks $HMMJ.CA $WEED.CA $BHC $CGC $ACB.CA $IMV.CA
Nov 09, 2018 10:58 am
INK Staff's picture
What do insiders prefer: traditional or alternative Healthcare stocks? https://www.canadianinsider.com/featured-report/what-do-insiders-prefer-traditional-or-alternative-healthcare-stocks $HMMJ.CA $WEED.CA $BHC $CGC $ACB.CA $IMV.CA
Nov 09, 2018 10:58 am
Ted Dixon's picture
Insiders still buying at ImmunoVaccine. Free INK Research company report for logged in users: https://www.canadianinsider.com/featured-report/insiders-still-buying-immunovaccine $IMV.CA $IBB
May 12, 2017 09:09 am
INK Staff's picture
Insiders still buying at ImmunoVaccine. Free INK Research company report for logged in users: https://www.canadianinsider.com/featured-report/insiders-still-buying-immunovaccine $IMV.CA $IBB
May 12, 2017 09:09 am

Twitter

Search (past week) for $IMV.CA

StockTwits